SCHEMBL4670696

SCHEMBL4670696

O=C(Cc1ccsc1Cc1ccccc1F)C(=O)c1nn[nH]n1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK8 P45983 1/20 0.36
PTGDR2 Q9Y5Y4 1/20 0.34
HPGD P15428 2/20 0.33
CES1 P23141 1/20 0.33
NCEH1 Q6PIU2 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
ABL1 P00519 1/20 0.32
NPC1 O15118 3/20 0.32
RAB9A P51151 3/20 0.32
KDM4E B2RXH2 2/20 0.32
AR P10275 1/20 0.32
CXCR3 P49682 2/20 0.32
ALDH1A1 P00352 2/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
ERCC5 P28715 1/20 0.32
FEN1 P39748 1/20 0.32
MEN1 O00255 2/20 0.31
KMT2A Q03164 2/20 0.31
MAPT P10636 1/20 0.31
MAPK1 P28482 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4673452 0.91 MAPK8 (0.36) MAPK8PTGDR2HPGDCES1NCEH1
SCHEMBL4675661 0.85 CES1 (0.42) MAPK8CES1NCEH1ALDH1A1ERCC5
SCHEMBL4670964 0.83 MAPK8 (0.34) MAPK8PTGDR2CES1NCEH1CXCR3
SCHEMBL4675774 0.83 KDM4E (0.36) MAPK8HPGDSMN1; SMN2ABL1NPC1
SCHEMBL4676361 0.82 PTGDR2 (0.35) PTGDR2CES1NCEH1NPC1RAB9A
SCHEMBL4671231 0.82 FFAR2 (0.39) MAPK8PTGDR2CES1NCEH1RAB9A
SCHEMBL4677164 0.82 PTGDR2 (0.38) PTGDR2HPGDCES1NCEH1NPC1
SCHEMBL4671652 0.82 P2RX7 (0.33) HPGDCES1NCEH1SMN1; SMN2RAB9A
SCHEMBL4674274 0.80 MAPK8 (0.32) MAPK8CES1NCEH1MAPT
SCHEMBL4670733 0.80 AR (0.36) PTGDR2CES1NCEH1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 MAPK8 2178/4885PTGDR2 4591/4885HPGD 2816/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.